<DOC>
	<DOCNO>NCT01540409</DOCNO>
	<brief_summary>The primary objective study ass ongoing efficacy , safety , tolerability additional 212 week treatment eteplirsen injection Duchenne muscular dystrophy ( DMD ) subject successfully complete 28 week eteplirsen study : Study 4658-us-201 . This study also evaluate correlation biomarkers DMD clinical status participate DMD subject .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Rollover Study Eteplirsen Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>This open label , multiple dose extension study ass ongoing efficacy , safety , tolerability weekly intravenous ( IV ) infusion eteplirsen DMD subject successfully complete Study 4658-us 201 . Subjects opportunity enroll study last visit Study 4658-us-201 ( Week 28 ) . Eligible subject receive weekly IV infusion eteplirsen ( 50 30 mg/kg ) additional 212 week . Subjects receive dose eteplirsen receive Study 4658-us-201 . Subjects thereafter continue receive weekly IV infusion eteplirsen additional 72 week period ( week 284 ) . If commercial eteplirsen become available additional 72 week period , participation study discontinue subject transition commercial eteplirsen . Safety , efficacy , pharmacokinetic ( PK ) , biomarker assessment perform scheduled visit ; adverse event ( AEs ) concomitant medication therapies continuously monitor . If review data open label study suggest continue treatment eteplirsen warrant , study may extend protocol amendment subject successfully complete study may opportunity participate separate follow , open label eteplirsen study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>A subject must meet follow criterion eligible study . 1 . The subject and/or parent/legal guardian willing able provide sign informed consent . 2 . The subject successfully complete 28 week treatment Study 4658US201 . 3 . The subject parent ( ) legal guardian ( ) able understand comply study procedure requirement . A subject meet follow criterion exclude study . 1 . The subject prior ongoing medical condition , Investigator 's opinion , could adversely affect safety subject make unlikely course treatment followup would complete impair assessment study result .</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DMD , Duchenne , Eteplirsen , dystrophy , dystrophin , exon 51</keyword>
</DOC>